

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Dupilumab for treating moderate to severe chronic obstructive pulmonary disease ID6235

Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
 Company Sanofi (dupilumab) Patient/carer groups Action on Smoking and Health (ASH) Asthma + Lung UK Breathing Matters NARA – The Breathing Charity South Asian Health Foundation Specialised Healthcare Alliance Healthcare professional groups Association for Respiratory Nurses British Geriatrics Society British Thoracic Society ILD-IN: Interstitial Lung Diseases Interdisciplinary Network National Heart and Lung Institute Primary Care Respiratory Society UK Royal College of General Practitioners Royal College of Pathologists Royal College of Physicians Royal College of Physicians Royal Society of Medicine UK Clinical Pharmacy Association Others Department of Health and Social Care NHS England 	 All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Chest, Heart and Stroke Scotland Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NOrthern Ireland Chest, Heart and Stroke Association Scottish Medicines Consortium Welsh Government Welsh Government Welsh Health Specialised Services Committee Possible comparator companies Aspire Pharma Ltd (azithromycin) AstraZeneca UK Limited (roflumilast) Aurobindo Pharma – Milpharm Ltd. (roflumilast, azithromycin) Pfizer Limited (azithromycin) Sandoz Limited (azithromycin) Thea Pharmaceuticals Ltd (azithromycin)
	British Association for Lung Research

Provisional stakeholder list for the evaluation of dupilumab for treating moderate to severe chronic obstructive pulmonary disease ID6235



Consultees	Commentators (no right to submit or appeal)
	 Cochrane Airways Group Cochrane UK Genomics England MRC Clinical Trials Unit National Institute for Health Research
	 Associated Public Health group Public Health Wales UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).


Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

Provisional stakeholder list for the evaluation of dupilumab for treating moderate to severe chronic obstructive pulmonary disease ID6235





Provisional stakeholder list for the evaluation of dupilumab for treating moderate to severe chronic obstructive pulmonary disease ID6235